Laura Shawver, Silverback

Lau­ra Shawver is about to join a line­up of biotech CEOs en­joy­ing overnight for­tunes, cour­tesy of the biotech IPO boom

Lau­ra Shawver capped 2019 with an $88 mil­lion wind­fall from the sale of Syn­thorx to Sanofi. And she piv­ot­ed right back in­to the sweet spot in 2020.

Just months af­ter the sale, the se­r­i­al en­tre­pre­neur re­turned to the helm of a start­up — tak­ing the lead post at Sil­ver­back Ther­a­peu­tics, which had just raised $78 mil­lion. Now she’s cap­tain­ing a team that plans to end 2020 with a bang, up­siz­ing their IPO of­fer and boost­ing the stock price range to­day as they eye a gain of $200 mil­lion—plus. The un­der­writ­ers could add sig­nif­i­cant­ly more than that if they take their shares at the IPO price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.